637286
Last Update Posted: 2009-04-06
Recruiting has ended
All Genders accepted | 18 Years-65 Years |
120 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
ZAP, US. Zomig for Appropriate for Primary Care
The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months
Eligibility
Relevant conditions:
Migraine
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov